S860
Clinical - Mixed sites & palliation
ESTRO 2026
Oligometastases were defined according to ESTRO/EORTC consensus. Inclusion criteria were as follows: ECOG PS ≤ 2, written consent, up to 5 lesions treated at the same time, patients treated with radiotherapy schedules applying minimum 6 Gy per fraction. Primary endpoint of the study was local control (LC); acute and late toxicity, distant progression-free survival (DPFS), time-to-next systemic treatment (TNST), polymetastatic-free survival (PMFS) and overall survival (OS) were secondary endpoints. Toxicity was assessed according to CTCAE criteria v5.0. Survival estimates were performed using Kaplan Meier method, uni- and multi-variate analyses were carried out to identify any potentially significant correlation. Results: Between April 2020 and July 2025 a total of 29 oligometastatic lesions located in the peritoneum or in the abdominal wall detected in 21 patients received SBRT with Helical Tomotherapy. Among them, 26 lesions in 20 patients were available for clinical evaluation. All cases have been assessed in multidisciplinary team. Only in three patients out of 20, more than one lesion received SBRT: 2 lesions in 2 patients, and five lesions in a single case of colorectal cancer with ongoing 3rd line systemic treatment. Median total dose was 30 Gy (27-35 Gy) in 5 fractions (3-5). The most frequent primary neoplasm was ovarian cancer in 14/20, endometrial in 2/20, while the remaining were colorectal, vaginal, pancreatic and non-small-cell lung cancer. Four lesions were located in the abdominal wall, while the remaining 22 in the peritoneum. Concurrent systemic therapy was administered in 18/20 patients. With a median follow- up of 19 months (range, 6-59), 1-year LC was 95%, while 1-year DPFS, PMFS, TNTS and OS rates were 54%, 69%, 61% and 83%, respectively. At statistical analysis, abdominal wall lesions were significantly related to improved OS rates (p=0.03), as well as patients developing a further oligometastatic progression treated with a second course of SBRT (p=0.04). No G ≥ 3 adverse events occurred. Conclusion: Our preliminary data support the use of SBRT in selected cases of isolated peritoneal or abdominal wall oligometastases disease located in the peritoneum or in the abdominal wall with excellent results in terms of tolerability and promising clinical outcomes. Keywords: oligometastases; SBRT; peritoneum
digoxin for five days, then continue through the course of treatment. Using CT, PET and MRI imaging, we showed efficacy in cervical, breast, bladder, lung, pancreatic, brain, and squamous cell and melanoma skin cancers. Sodium channels were stimulated using a custom designed pulsed electric field stimulator. We have treated companion animals with nasal and oral carcinomas as well as three human patients with facial squamous cell skin cancers, three with facial melanoma, and other carcinomas that overexpress VGSCs. Results: Results: Thus far, none of the companion animals have returned with further cancer. Moreover, nearly all patients reported an increase in energy and appetite as soon as the day after the first treatment. Post- treatment scaring was minimal or nonexistent. They also report no adverse effects. None have shown need of further treatment. Conclusion: Conclusion: TOL appears to be a carcinoma treatment with no adverse effects, no scaring and improvement in quality of life. Keywords: osmotic lysis, electric field, sodium channel Digital Poster 343 STEREOTACTIC BODY RADIOTHERAPY FOR PERITONEAL OR ABDOMINAL WALL OLIGOMETASTASES: PRELIMINARY RESULTS FROM A MONO-INSTITUTIONAL ANALYSIS Francesco Cuccia 1 , Salvatore D'Alessandro 1 , Marina Campione 2,3 , Vanessa Figlia 1 , Gianluca Mortellaro 1 , Antonio Spera 1 , Antonino Abbate 4 , Giulia Musicò 4 , Salvatore Russo 5 , Carlo Messina 5 , Giuseppe Carruba 2 , Livio Blasi 5 , Giuseppe Ferrera 1 1 Radiation Oncology, ARNAS Civico Hospital, Palermo, Italy. 2 Clinical Research, ARNAS Civico Hospital, Palermo, Italy. 3 Biostatistics, Kore University, Enna, Italy. 4 Gynecology Oncology, ARNAS Civico Hospital, Palermo, Italy. 5 Medical Oncology, ARNAS Civico Hospital, Palermo, Italy
Purpose/Objective: Peritoneal carcinosis can occur in several
gastrointestinal or gynecological malignancies and its prognosis is usually poor. As more effective systemic agents have revolutionized the overall survival of metastatic patients, isolated peritoneal or abdominal wall metastases might benefit from local treatments and Stereotactic Body Radiotherapy (SBRT) might be considered in selected patients with oligometastatic presentation. Material/Methods:
Digital Poster 458
Intraoperative Radiotherapy for Resectable Brain Metastases: Systematic Review, Meta-Analysis and Update from the Largest Single Center Experience
Made with FlippingBook - Share PDF online